Baseline cardiovascular risk assessment in patients receiving proteasome inhibitors for haematological malignancies: a tertiary referral centre experience
Clicks: 1
ID: 323410
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #275 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction Thanks to encouraging trial results, proteasome inhibitors have become mainstays of therapy in patients with newly diagnosed and relapsed multiple myeloma. Similar beneficial findings have been identified with their use in waldenström’s macroglobulinaemia. Patients treated with proteasome inhibitors have a high incidence of coexistent comorbidities leading to an increased baseline cardiovascular risk, and newly developed heart failure is a frequently developed adverse effect on treatment. The European Society of Cardiology have published surveillance guidance for patients receiving proteasome inhibitors, including baseline cardiovascular risk assessment and on-treatment monitoring. Purpose We performed a single centre study to assess the quality of pre-treatment risk assessment in patients with haematological malignancies receiving proteasome inhibitor-based treatments. Methods Information was collected from an academic tertiary referral hospital. Data was retrospectively extracted on patients diagnosed with multiple myeloma or waldenström’s macroglobulinaemia who were treated with proteasome inhibitors using pharmacy dispensing records. Electronic and handwritten records were reviewed for each patient to identify for the presence of comorbidities, cardiovascular biomarker levels, ECG findings, echocardiography reports, and details on referrals to the on-site cardiology service prior to commencing treatment. Baseline cardiovascular risk was calculated for each patient using the Heart Failure Association-International Cardio-Oncology Society risk score. Results Over the study period, 216 patients with multiple myeloma or waldenström’s macroglobulinaemia were treated with proteasome inhibitors. 50% of patients were male, 50% were female. 88.9% of patients had multiple myeloma; 11.1% had waldenström’s macroglobulinaemia. 83.3% of patients received bortezomib; 16.7% received carfilzomib. 50%, 33.3% and 16.7% of patients had high, moderate and low baseline cardiovascular risk scores respectively. 66.7% and 61.1% of patients did not have baseline troponins and BNP/NT-pro-BNPs taken respectively. 55.5% and 72.2% of patients did not undergo pre-treatment ECGs or transthoracic echocardiographs respectively. Conclusions Patients with multiple myeloma treated with proteasome inhibitors are frequently not receiving a full baseline cardiovascular risk assessment prior to commencing treatment. Future efforts will need to focus on improved compliance rates to ensure appropriate risk stratification, and appropriate cardiovascular monitoring, while on treatment.
| Reference Key |
openalex_W7172288698
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | M Mc Kenna, A O'flynn, R Desmond |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.104
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.